(2 R,6 R)-Hydroxynorketamine Exerts mGluR2-Dependent Antidepressant Actions

被引：0
作者：
Zanos, Panos [1 ]
Highland, Jaclyn [1 ]
Georgiou, Polymnia [1 ]
Stewart, Brent [1 ]
Bonaventura, Jordi [1 ]
Lam, Sherry [1 ]
Zarate, Carlos, Jr. [1 ]
Michaelides, Michael [1 ]
Gould, Todd [1 ]
机构：
[1] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2018年 / 43卷
关键词：
Ketamine; Hydroxynorketamine; Depression; Antidepressant; mGlu; 2/3; Receptor;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
T31
引用
收藏
页码：S243 / S243
页数：1
相关论文
共 50 条
  • [41] (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine are Prophylactic Against Stress-Induced Depressive-Like Behavior in Female Mice
    Chen, Briana
    LaGamma, Christina
    Brachman, Rebecca
    Xu, Xiaoming
    Deng, Shi-Xian
    Landry, Donald
    Denny, Christine
    NEUROPSYCHOPHARMACOLOGY, 2017, 42 : S560 - S561
  • [42] Intranasal (2R, 6R)-hydroxynorketamine for acute pain: Behavioural and neurophysiological safety analysis in mice
    Goswami, Nidhi
    Aleem, Mohd
    Manda, Kailash
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2023, 50 (02) : 169 - 177
  • [43] Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors
    Hildegard A. Wulf
    Caroline A. Browne
    Carlos A. Zarate
    Irwin Lucki
    Psychopharmacology, 2022, 239 : 2309 - 2316
  • [44] TRKB interaction with PSD95 is associated with latency of fluoxetine and 2R,6R-hydroxynorketamine
    Fred, Senem Merve
    Moliner, Rafael
    Antila, Hanna
    Engelhardt, Karl-Alexander
    Schlueter, Oliver M.
    Casarotto, Plinio C.
    Castren, Eero
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2023, 57 (08) : 1215 - 1224
  • [45] Now is the time for (2R,6R)-hydroxynorketamine to be viewed independently from its parent drug
    Chaki, Shigeyuki
    Yamaguchi, Jun-ichi
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2018, 175 : 24 - 26
  • [46] Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors
    Wulf, Hildegard A.
    Browne, Caroline A.
    Zarate, Carlos A.
    Lucki, Irwin
    PSYCHOPHARMACOLOGY, 2022, 239 (07) : 2309 - 2316
  • [47] Effectiveness of Ketamine and (2R,6R)-Hydroxynorketamine to Reverse Anhedonia Subtypes Induced by Stress in Mice
    Georgiou, Polymnia
    Rajasekar, Thatchana
    Liu, Chao
    Zanos, Panos
    Gould, Todd
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 136 - 136
  • [48] Interactions of (2S,6S;2R,6R)-Hydroxynorketamine, a Secondary Metabolite of (R,S)-Ketamine, with Morphine
    Lilius, Tuomas O.
    Viisanen, Hanna
    Jokinen, Viljami
    Niemi, Mikko
    Kalso, Eija A.
    Rauhala, Pekka V.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 122 (05) : 481 - 488
  • [49] (2R,6R)-hydroxynorketamine targeting the basolateral amygdala regulates fear memory
    Xu, Yuanyuan
    Yu, Zhenfei
    Chen, Si
    Li, Zhenlong
    Long, Xiting
    Chen, Mengxu
    Lee, Chau-Shoun
    Peng, Hsien-Yu
    Lin, Tzer-Bin
    Hsieh, Ming-Chun
    Lai, Cheng -Yuan
    Chou, Dylan
    NEUROPHARMACOLOGY, 2023, 225
  • [50] A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers
    Raja, Shruti M.
    Guptill, Jeffrey T.
    Mack, Michelle
    Peterson, Marni
    Byard, Stephen
    Twieg, Robert
    Jordan, Lynn
    Rich, Natalie
    Castledine, Richard
    Bourne, Samuel
    Wilmshurst, Martin
    Oxendine, Sarah
    Avula, Satya G. C.
    Zuleta, Helen
    Quigley, Paul
    Lawson, Sheila
    McQuaker, Stephen J.
    Ahmadkhaniha, Reza
    Appelbaum, Lawrence G.
    Kowalski, Kevin
    Barksdale, Chineta T.
    Gufford, Brandon T.
    Awan, Asaad
    Sancho, Alfredo R.
    Moore, Max C.
    Berrada, Karim
    Cogan, Gregory B.
    DeLarosa, Jesse
    Radcliffe, Jeanne
    Pao, Maryland
    Kennedy, Michelle
    Lawrence, Quentin
    Goldfeder, Lisa
    Amanfo, Leslie
    Zanos, Panos
    Gilbert, Jessica R.
    Morris, Patrick J.
    Moaddel, Ruin
    Gould, Todd D.
    Zarate, Carlos A.
    Thomas, Craig J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (05) : 1314 - 1324
12345